These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 34825292)

  • 41. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.
    Wang D; Prager BC; Gimple RC; Aguilar B; Alizadeh D; Tang H; Lv D; Starr R; Brito A; Wu Q; Kim LJY; Qiu Z; Lin P; Lorenzini MH; Badie B; Forman SJ; Xie Q; Brown CE; Rich JN
    Cancer Discov; 2021 May; 11(5):1192-1211. PubMed ID: 33328215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma.
    Li G; Zhang Z; Cai L; Tang X; Huang J; Yu L; Wang G; Zhong K; Cao Y; Liu C; Wang Y; Tong A; Zhou L
    Oncoimmunology; 2021; 10(1):1983306. PubMed ID: 34595061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
    Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
    PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-invasive monitoring of the kinetic infiltration and therapeutic efficacy of nanoparticle-labeled chimeric antigen receptor T cells in glioblastoma via 7.0-Tesla magnetic resonance imaging.
    Xie T; Chen X; Fang J; Xue W; Zhang J; Tong H; Liu H; Guo Y; Yang Y; Zhang W
    Cytotherapy; 2021 Mar; 23(3):211-222. PubMed ID: 33334686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimizing T Cell-Based Therapy for Glioblastoma.
    Karachi A; Dastmalchi F; Nazarian S; Huang J; Sayour EJ; Jin L; Yang C; Mitchell DA; Rahman M
    Front Immunol; 2021; 12():705580. PubMed ID: 34421912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
    Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
    Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
    Shiina S; Ohno M; Ohka F; Kuramitsu S; Yamamichi A; Kato A; Motomura K; Tanahashi K; Yamamoto T; Watanabe R; Ito I; Senga T; Hamaguchi M; Wakabayashi T; Kaneko MK; Kato Y; Chandramohan V; Bigner DD; Natsume A
    Cancer Immunol Res; 2016 Mar; 4(3):259-68. PubMed ID: 26822025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives.
    Karschnia P; Teske N; Thon N; Subklewe M; Tonn JC; Dietrich J; von Baumgarten L
    Neurology; 2021 Aug; 97(5):218-230. PubMed ID: 33986138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
    Daubon T; Hemadou A; Romero Garmendia I; Saleh M
    Front Immunol; 2020; 11():585616. PubMed ID: 33154756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture.
    Ponterio E; De Maria R; Haas TL
    Front Immunol; 2020; 11():565631. PubMed ID: 33101285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gastrodin synergistically increases migration of interleukin-13 receptor α2 chimeric antigen receptor T cell to the brain against glioblastoma multiforme: A preclinical study.
    Huang S; Bai Y; An Z; Xu C; Zhang C; Wang F; Zhong C; Zhong X
    Phytother Res; 2023 Dec; 37(12):5947-5957. PubMed ID: 37748098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current and future perspectives of chimeric antigen receptors against glioblastoma.
    Zhang J; Siller-Farfán JA
    Immunother Adv; 2022; 2(1):ltac014. PubMed ID: 36284838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring miRNA therapies and gut microbiome-enhanced CAR-T cells: advancing frontiers in glioblastoma stem cell targeting.
    Sandhanam K; Tamilanban T; Bhattacharjee B; Manasa K
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Oct; ():. PubMed ID: 39382681
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
    Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
    Front Immunol; 2019; 10():2683. PubMed ID: 31798595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?
    Gatto L; Di Nunno V; Franceschi E; Tosoni A; Bartolini S; Brandes AA
    Drugs; 2022 Apr; 82(5):491-510. PubMed ID: 35397073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
    Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
    J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.